Full-Time

Senior Data Engineer

Data Operations

Posted on 6/27/2025

RELX

RELX

1,001-5,000 employees

Global information analytics and decision tools

No salary listed

London, UK

In Person

Category
Data & Analytics (1)
Required Skills
Microsoft Azure
Python
Airflow
SQL
Apache Kafka
AWS
Data Analysis
Snowflake
Google Cloud Platform
Requirements
  • Considerable experience in Data Engineering with strong focus on Data Management and Data Quality
  • Bachelor’s Degree (Engineering/Computer Science preferred but not required); or equivalent experience required
  • Deep proficiency in Python, SQL, Cloud Platforms (AWS, GCP, Azure). Data Warehousing (Snowflake), Orchestration (Airflow, Rundeck), Streaming (Kafka)
  • Continuous engagement with Data Science and Analytics colleagues to understand requirements for our data-assets and empower them with best possible data, to create high value analytical services
  • Ownership of assigned data products, including data model design, end-to-end data pipeline delivery, data product quality monitoring, requirements analysis and issue resolution
  • Enthusiastic attitude to explore and implement advanced data technologies and tools
  • Working with other tech teams to define data requirements for external data products e.g., APIs, Data Marketplace offerings etc.
  • Create data-to-value framework, which enables data value tracking from ingestion to customer value realisation
  • A team player who works collaboratively and possesses excellent communications skills with ability to communicate technical details in business terminology
  • Demonstrated success in managing multiple deliverables concurrently and prioritising effectively
  • Detail-orientated with strong problem-solving skills, innovative thinking and self-motivation in learning and exploring applications
  • Capable of providing coaching and support to transfer technical and data knowledge, fostering a collaborative team environment
  • Contribute to continuous improvement initiatives and process enhancements.
Responsibilities
  • Data Pipeline Development: Design, develop, and optimize robust data pipelines and ETL processes to ensure efficient data flow and integration
  • Data Infrastructure Management: Manage and enhance our data infrastructure to support performance, scalability, and long-term reliability
  • Advanced Analytics Support: Build and maintain data models, data marts, and data lakehouse architectures to support data science initiatives, advanced analytics and reporting
  • Data Quality Assurance: Implement data quality checks to maintain accuracy and consistency across all data sources
  • Technology Exploration: Explore and implement advanced data technologies and tools
  • Drive Continuous Improvement: Identify opportunities to streamline processes and improve the efficiency of our data pipelines
  • Mentor and Support Team Members: Provide guidance and mentorship to junior engineers and support team to tackle technical challenges together
  • Stakeholder Collaboration: Work closely with cross-functional teams to understand data requirements and deliver solutions that meet business needs and collaborate with Analysts, Data Scientists, product owners, and business stakeholders to deliver high-impact, AI-driven solutions.

RELX is a global provider of information-based analytics and decision tools for professionals across scientific, technical, medical, legal, risk, business, and exhibitions industries. It operates in four segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. Its products combine large datasets, analytics, and decision-support tools to help researchers, healthcare professionals, lawyers, and business leaders make informed choices, improve productivity, and achieve better outcomes. Revenue mainly comes from subscriptions, with additional income from transactional sales and advertising. RELX differentiates itself through its deep data assets, specialized industry knowledge, and multi-segment offerings that span content, analytics, and decision-support services. The company pursues a goal of delivering trusted information and insights while supporting corporate responsibility and alignment with the UN SDGs through its products and partnerships.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1894

Simplify Jobs

Simplify's Take

What believers are saying

  • 7% revenue growth and 9% adjusted operating profit increase in 2025 from AI tool adoption.
  • LexisNexis customers increasingly adopt AI-assisted tools, driving subscription revenue expansion.
  • Government sector expansion through enhanced fraud detection capabilities protects critical social safety nets.

What critics are saying

  • Anthropic's legal AI agent directly competes with Lexis+AI, eroding subscription revenue within 6-12 months.
  • EU AI Act enforcement July 2026 classifies Protégé as high-risk, imposing fines up to 6% revenue.
  • Thomson Reuters' Westlaw Precision AI captured 15% market share through superior case prediction accuracy.

What makes RELX unique

  • Proprietary database of 200 billion legal documents dating to 1873 cannot be replicated by AI providers.
  • Acquired Doctrine in 2025 to strengthen AI capabilities across European legal market segments.
  • Appointed fraud prevention expert Glenn Prager April 2025 to enhance government risk solutions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Mental Health Support

Family Planning Benefits

Health Savings Account/Flexible Spending Account

Flexible Work Hours

Remote Work Options

Company News

Business Insider
Mar 1st, 2026
LexisNexis CEO dismisses AI threat as company reports 7% revenue growth

LexisNexis CEO Sean Fitzpatrick has dismissed investor concerns that AI threatens the legal software giant, saying proprietary data gives it a competitive advantage. Shares of parent company Relx fell 14% on 3 February following Anthropic's launch of an AI agent that drafts legal briefs, and are down 17% year-to-date. Fitzpatrick said LexisNexis's database of 200 billion legal documents, including content from Shepard's Citations dating to 1873, cannot be replicated by AI model makers. The company doesn't license its proprietary data to general-purpose AI providers. Relx reported 7% revenue growth for 2025 and 9% increase in adjusted operating profit, driven by customers adopting AI tools. LexisNexis is hiring and hasn't conducted AI-related redundancies.

Yahoo Finance
Feb 22nd, 2026
RELX's LexisNexis launches AI-powered identity management platform for healthcare

LexisNexis Risk Solutions, a wholly owned subsidiary of RELX, has launched a new identity management platform for the healthcare sector. Announced on 19 February, the tool combines identity verification, matching and enrichment capabilities with AI-powered authentication to enhance security throughout patients' healthcare journeys. The platform integrates LexisNexis IDVerse and offers enhanced identity verification, resolution and fraud protection. For healthcare professionals, it accelerates onboarding processes, automates processing and provides digital checks to prevent fraud. RELX is a global information and analytics company serving professional and business customers across scientific, technical, medical, legal and risk management markets.

PR Newswire
Jun 4th, 2025
Elsevier Unveils Rigorous Evaluation Framework To Mitigate Risk In Generative Ai Clinical Decision Support Tools

Clinician-centered framework will be featured in upcoming issue of the Open AccessJournal of the American Medical Informatics Association (JAMIA)Initial evaluations of ClinicalKey AI show high accuracy and usefulness in responses amongst cliniciansNEW YORK, June 4, 2025 /PRNewswire/ -- Elsevier, a global leader in medical information and data analytics, unveiled a groundbreaking evaluation framework for assessing the performance and safety of generative AI-powered clinical reference tools. This innovative approach has been developed for all Elsevier Health generative AI solutions, including ClinicalKey AI, Elsevier's advanced clinical decision support platform, and sets a new standard for responsible AI integration in healthcare. It will be featured in a future issue of the Open Access Journal of the American Medical Informatics Association (JAMIA).The framework, designed with input from clinical subject matter experts across multiple specialties, evaluates AI-generated responses along five critical dimensions: query comprehension, response helpfulness, correctness, completeness, and potential for clinical harm. It serves as a comprehensive assessment to ensure that AI-powered tools not only provide accurate and relevant information but also align with the practical and current needs of healthcare professionals at the point of care.Omry Bigger, President of Clinical Solutions at Elsevier: "This evaluation framework not only supports innovation and advancements to improve patient care but adds an extra layer of review and assessment to ensure physicians are armed with the most accurate information possible. It's a critical step in the implementation of responsible AI for healthcare providers and patients."In a recent evaluation study of ClinicalKey AI, Elsevier worked with a panel of 41-board certified physicians and clinical pharmacists to rigorously test responses generated by the tool for a diverse set of clinical queries. That panel evaluated 426 query-response pairs, and results demonstrated impressive performance, with 94.4% of responses rated as helpful, 95.5% assessed as completely correct, with just 0.47% flagged for potential improvements.Leah Livingston, Director of Generative AI Evaluation for Health Markets at Elsevier, said: "These results reflect not just strong performance, but the real value of bringing clinicians into the evaluation process

PharmiWeb.com
May 7th, 2025
Elsevier Adds Half A Million Records From Clinicaltrials.Gov To Embase, Enabling A Seamless Search Experience In The World’S Most Comprehensive Biomedical Database

London, 6 May 2025 – Elsevier, a global leader in information and analytics, is announcing the addition of half a million records from ClinicalTrials.gov to its leading biomedical literature database, Embase. The integration will enable researchers to seamlessly view high-quality information on clinical research studies and their results alongside the peer-reviewed literature, in-press publications and conference abstracts already available in Embase. Researchers will be able to conduct more comprehensive evidence and literature searches while having the confidence they will never miss important updates relevant to their drug, therapy, or medical device. Clinical trials data is a vital component of biomedical literature search, helping pharmaceutical and medical device companies stay informed about the latest scientific advancements, regulatory requirements, and competitive insights to support evidence-based decision-making. However, gathering data from multiple sources is currently prone to errors and is time-consuming, such as the duplication of search results, which slows research and regulatory processes. As new therapies and devices are developed and RD organizations seek collaborative partners, they must undertake thorough searches and justifications of evidence

PR Newswire
May 6th, 2025
Elsevier Adds Half A Million Records From Clinicaltrials.Gov To Embase, Enabling A Seamless Search Experience In The World'S Most Comprehensive Biomedical Database

Data from studies conducted in more than 200 countries supports greater access to research and facilitates systematic reviews, clinical trial design, medical device approvals and improved drug safetyLONDON, May 6, 2025 /PRNewswire/ -- Elsevier, a global leader in information and analytics, is announcing the addition of half a million records from ClinicalTrials.gov to its leading biomedical literature database, Embase. The integration will enable researchers to seamlessly view high-quality information on clinical research studies and their results alongside the peer-reviewed literature, in-press publications and conference abstracts already available in Embase. Researchers will be able to conduct more comprehensive evidence and literature searches while having the confidence they will never miss important updates relevant to their drug, therapy, or medical device.Clinical trials data is a vital component of biomedical literature search, helping pharmaceutical and medical device companies stay informed about the latest scientific advancements, regulatory requirements, and competitive insights to support evidence-based decision-making. However, gathering data from multiple sources is currently prone to errors and is time-consuming, such as the duplication of search results, which slows research and regulatory processes. As new therapies and devices are developed and R&D organizations seek collaborative partners, they must undertake thorough searches and justifications of evidence. This process becomes challenging when data must be sourced from differing platforms, and regulatory and compliance requirements continue to evolve.The addition of ClinicalTrials.gov data to Embase will improve researcher workflows by making clinical data searchable within Embase's user-friendly interface

INACTIVE